Press releases
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Jan 2, 2020Conference schedule includes 38th Annual J.P. Morgan Healthcare Conference and Investor Update at NANS 2020
Boston Scientific Corporation (NYSE: BSX) will participate in the 38th Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, 2020 in San Francisco, California. Mike Mahoney, chairman...
Dec 13, 2019U.S. Food and Drug Administration Granted EXALT Model D Single-Use Duodenoscope Breakthrough Device Designation, Expediting Physicians' Access to a New, Sterile Device for Each PatientThe EXALT Model D Duodenoscope is the first and only FDA cleared single-use duodenoscope on the market.
-
Nov 21, 2019
Boston Scientific Corporation is scheduled to participate in two investor conferences in December 2019.
-
Nov 12, 2019
Boston Scientific completed a public offering of €900.0 million aggregate principal amount of 0.625% Senior Notes due 2027.
-
Nov 6, 2019
Boston Scientific announced a public offering of €900.0 million aggregate principal amount of 0.625% Senior Notes due 2027.
-
Nov 5, 2019
Boston Scientific announced the commencement of a cash tender offer for up to $1.0 billion of outstanding senior notes.
-
Nov 5, 2019Late-breaking clinical trial data demonstrate high rates of primary patency and significantly lower rates of clinically-driven target lesion revascularization for peripheral drug-eluting device portfolio
Today, Boston Scientific (NYSE: BSX) announced positive data for two devices within the peripheral drug-eluting product portfolio during separate late-breaking clinical trial presentations at...
-
Nov 5, 2019
Boston Scientific Corporation (the "Company") (NYSE:BSX) today announced that, pursuant to the previously announced cash tender offer (the "Tender Offer") for up to $1.0 billion aggregate...
-
Nov 1, 2019
Boston Scientific will participate in four conferences in November 2019. Learn how to join the webcasts or watch the replays for each event.
-
Oct 23, 2019
"Our third quarter results reflect accelerated growth,” said Mike Mahoney, chairman and CEO, Boston Scientific. Read the October 23, 2019 announcement.